GEN News Highlights - 3/28/08

Lyle — Fri, 28 Mar 2008 11:15:46 -0400

Link to All Articles

Mar 27 2008, 11:45 AM EST
Otsuka Allies with MethylGene for R&D in Ocular Diseases other than Cancer
Payments to MethylGene include $3.875 million in the first 18 months, further research and milestone fees, and an equity investment of up to $3 million.Full Story

Mar 27 2008, 11:39 AM EST
PharmAthene Retains GTC's Manufacturing Services for Protexia
Product is intended for victims of chemical nerve agent attack.Full Story

Mar 27 2008, 11:50 AM EST
Avanir to Get $40M to Complete Trial on Drug for Pseudobulbar Affect
Study will use lower dose of Zenvia to address safety concerns brought up in the FDA's approvable letter.Full Story

Mar 26 2008, 12:24 PM EST
Lilly Beefs Up Biomarker Analysis Deal with HistoRx
Lilly will leverage the Aqua tool in more therapeutic programs, and HistoRx will work on customized assays.Full Story

Mar 25 2008, 12:09 PM EST
Metabolon and the Harvard-Partners Healthcare Collaborate to Refine Warfarin Theranostic
Metabolomic profile will be assessed along with genetic information to optimize dosing.Full Story

Mar 25 2008, 12:04 PM EST
Ceragenix Hands Over Rights to Preclinical HIV Pipeline to FirstPoint Biotech
The compounds will be evaluated for their use as drugs as well as incorporation into devices.Full Story

Mar 25 2008, 12:06 PM EST
ESA Biosciences and Waters to Provide Software to Integrate Respective Technologies
Data-interface module will better combine ESA's Corona CAD HPLC detector with Waters' Empower 2 chromatography platform.Full Story

Mar 24 2008, 11:11 AM EST
Scientists Uncover Protein Involved in Maintaining ES Cell Pluripotency
Nature paper shows that REST inhibits miR-21, which suppresses stem-cell self renewal and induces differentiation.Full Story

Mar 24 2008, 11:08 AM EST
Rosetta Genomics Identifies Source of Cancer of Unknown Primary with miRNAs
Overall sensitivity of this panel was approximately 85%, according to research in Nature Biotechnology.Full Story

GenEngNews.com

F.D.A. Reviewing H.I.V. Drugs for Heart Risk

Lyle — Fri, 28 Mar 2008 11:14:05 -0400

Link to Article

NYTimes.com

FDA probing suicide risks from asthma drug

Alex Hsieh on behalf of Professor Henry Wang — Thu, 27 Mar 2008 23:45:04 -0400

U.S. regulators on Thursday said they are probing a possible connection between Merck & Co's Singulair asthma drug and suicidal behavior.

Link to Article

MSNBC.com

Pharmaceutical Engineering

GEN News Highlights - 3/28/08

F.D.A. Reviewing H.I.V. Drugs for Heart Risk

FDA probing suicide risks from asthma drug